The Humanized Anti-HM1.24 Antibody Effectively Kills Multiple Myeloma Cells by Human Effector Cell-mediated Cytotoxicity
Overview
Molecular Biology
Affiliations
A mouse monoclonal antibody, anti-HM1.24 (IgG2a/kappa), binds to a surface antigen preferentially overexpressed on multiple myeloma (MM) cells, and exhibits potent antitumor cell activity against MM cells by antibody-dependent cell-mediated cytotoxicity (ADCC). To develop an antibody-based immunotherapy against MM, a humanized anti-HM1.24 antibody, in which all FRs correspond to naturally processed human FRs, has been successfully constructed with the aid of both the hybrid variable region and two-step design methods. This humanized anti-HM1.24 antibody (IgG1/kappa) is able to effectively induce ADCC against human myeloma KPMM2 and ARH77 cells in the presence of human PBMCs as effectively as a chimeric anti-HM1.24 antibody. The humanized anti-HM1.24 antibody, therefore, could be expected as a potent immunotherapeutic agent for MM patients.
A Novel T Cell-Engaging Bispecific Antibody for Treating Mesothelin-Positive Solid Tumors.
Yoon A, Lee S, Lee S, Lim S, Park Y, Song E Biomolecules. 2020; 10(3).
PMID: 32143496 PMC: 7175222. DOI: 10.3390/biom10030399.
Gong S, Osei E, Kaplan D, Chen Y, Meyerson H Int J Clin Exp Pathol. 2015; 8(2):1613-21.
PMID: 25973046 PMC: 4396245.
Bone marrow stromal antigen 2 (BST-2) DNA is demethylated in breast tumors and breast cancer cells.
Mahauad-Fernandez W, Borcherding N, Zhang W, Okeoma C PLoS One. 2015; 10(4):e0123931.
PMID: 25860442 PMC: 4393144. DOI: 10.1371/journal.pone.0123931.
Targeted therapy for HM1.24 (CD317) on multiple myeloma cells.
Harada T, Ozaki S Biomed Res Int. 2014; 2014:965384.
PMID: 25143955 PMC: 4124849. DOI: 10.1155/2014/965384.
Harada T, Ozaki S, Oda A, Tsuji D, Ikegame A, Iwasa M PLoS One. 2014; 8(12):e83905.
PMID: 24386306 PMC: 3873421. DOI: 10.1371/journal.pone.0083905.